• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

纤维蛋白原-白蛋白比率指数（FARI）作为预处理免疫治疗患者的一种特定预后生物标志物。

Fibrinogen-Albumin Ratio Index (FARI) as a Certain Prognostic Biomarker in Pretreated Patients with Immunotherapy.

作者信息

Guo Ziwei, Liang Jun

机构信息

Medical Oncology, Peking University International Hospital, Beijing, People's Republic of China.

Medical Oncology, Peking University Cancer Hospital and Institute, Beijing, People's Republic of China.

出版信息

Cancer Manag Res. 2021 May 24;13:4169-4180. doi: 10.2147/CMAR.S307272. eCollection 2021.

DOI:10.2147/CMAR.S307272
PMID:34079370
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8163584/
Abstract

PURPOSE

Immunotherapy has become the standard treatment for advanced tumors so that many biomarkers play parts in predicting prognosis and clinical outcome. Use of FARI is increasing, but there are no studies on its use prior to immunotherapy.

PATIENTS AND METHODS

A retrospective study prior to immunotherapies in advanced carcinoma used FARI and other biomarkers as clinical parameters from which to analyse data from January 2014 to November 2020. Data were presented in GraphPad Prism 7 and X-Tile and analyzed using IBM SPSS.

RESULTS

A total of 146 patients were enrolled in our study. FARI (with an optimal cut-off value of 11.1%) was divided into a high group, in connection with shorter OS mainly in patients with bone metastasis (120m vs 11.5m, 95% Cl: 12.17-23.83, SE: 2.974, =0.03), and a low group with a longer PFS (11.0m vs 5.0m, 95% Cl: 3.303-12.697, SE: 2.397, =0.03) in NSCLC but a shorter PFS (3.5m vs 5.5m, 95% Cl: 3.757-6.243, SE: 0.634, =0.01) in liver metastasis. FARI was not determined as an independent predictor of OS in patients undergoing medical therapies (>11.1% vs ≤11.1%, HR: 1.296, 95% Cl: 0.687-2.032, =0.314). ECOG (HR: 2.892, 95% Cl: 1.911-4.378, <0.001) can be an independent predictor for PFS and OS in advanced carcinoma.

CONCLUSION

Our findings highlight certain potential values for predicting prognosis but no outstanding biomarkers prior to immunotherapy according to FARI.

摘要

目的

免疫疗法已成为晚期肿瘤的标准治疗方法，因此许多生物标志物在预测预后和临床结果中发挥作用。FARI的使用正在增加，但尚无关于其在免疫治疗前使用情况的研究。

患者和方法

一项针对晚期癌症免疫治疗前的回顾性研究，使用FARI和其他生物标志物作为临床参数，分析2014年1月至2020年11月的数据。数据用GraphPad Prism 7和X-Tile呈现，并使用IBM SPSS进行分析。

结果

我们的研究共纳入146例患者。FARI（最佳临界值为11.1%）分为高分组，主要在骨转移患者中与较短的总生存期相关（120个月对11.5个月，95%可信区间：12.17 - 23.83，标准误：2.974，P = 0.03），以及低分组，在非小细胞肺癌中具有较长的无进展生存期（11.0个月对5.0个月，95%可信区间：3.303 - 12.697，标准误：2.397，P = 0.03），但在肝转移中无进展生存期较短（3.5个月对5.5个月，95%可信区间：3.757 - 6.243，标准误：0.634，P = 0.01）。在接受药物治疗的患者中，FARI未被确定为总生存期的独立预测因子（>11.1%对≤11.1%，风险比：1.296，95%可信区间：0.687 - 2.032，P = 0.314）。ECOG（风险比：2.892，95%可信区间：1.911 - 4.378，P < 0.001）可作为晚期癌症无进展生存期和总生存期的独立预测因子。

结论

我们的研究结果突出了某些预测预后的潜在价值，但根据FARI，在免疫治疗前没有突出的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d97/8163584/dff10b65d7dc/CMAR-13-4169-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d97/8163584/b9f887d7578f/CMAR-13-4169-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d97/8163584/c49a6c0e1061/CMAR-13-4169-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d97/8163584/e0bd5d25700c/CMAR-13-4169-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d97/8163584/c860d5dca171/CMAR-13-4169-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d97/8163584/dff10b65d7dc/CMAR-13-4169-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d97/8163584/b9f887d7578f/CMAR-13-4169-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d97/8163584/c49a6c0e1061/CMAR-13-4169-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d97/8163584/e0bd5d25700c/CMAR-13-4169-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d97/8163584/c860d5dca171/CMAR-13-4169-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d97/8163584/dff10b65d7dc/CMAR-13-4169-g0005.jpg

相似文献

1
Fibrinogen-Albumin Ratio Index (FARI) as a Certain Prognostic Biomarker in Pretreated Patients with Immunotherapy.纤维蛋白原-白蛋白比率指数（FARI）作为预处理免疫治疗患者的一种特定预后生物标志物。
Cancer Manag Res. 2021 May 24;13:4169-4180. doi: 10.2147/CMAR.S307272. eCollection 2021.
2
The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.纤维蛋白原-白蛋白比值指数在接受阿扎胞苷治疗的伴骨髓增生异常相关改变的骨髓增生异常综合征和急性髓系白血病患者中的预后价值。
Ann Hematol. 2021 Apr;100(4):953-957. doi: 10.1007/s00277-021-04440-z. Epub 2021 Feb 1.
3
Fibrinogen-Albumin Ratio Index (FARI): A More Promising Inflammation-Based Prognostic Marker for Patients Undergoing Hepatectomy for Colorectal Liver Metastases.纤维蛋白原-白蛋白比值指数（FARI）：一种用于预测结直肠癌肝转移患者行肝切除术预后的更有前途的炎症标志物。
Ann Surg Oncol. 2019 Oct;26(11):3682-3692. doi: 10.1245/s10434-019-07586-3. Epub 2019 Jul 1.
4
Prognostic value of the fibrinogen albumin ratio index (FARI) in nasopharyngeal carcinoma patients undergoing radiotherapy.纤维蛋白原-白蛋白比值指数（FARI）对接受放疗的鼻咽癌患者的预后价值。
Sci Rep. 2023 Nov 23;13(1):20630. doi: 10.1038/s41598-023-48029-0.
5
Preoperative Fibrinogen-Albumin Ratio Index (FARI) is a Reliable Prognosis and Chemoradiotherapy Sensitivity Predictor in Locally Advanced Rectal Cancer Patients Undergoing Radical Surgery Following Neoadjuvant Chemoradiotherapy.术前纤维蛋白原-白蛋白比值指数（FARI）是接受新辅助放化疗后行根治性手术的局部晚期直肠癌患者可靠的预后及放化疗敏感性预测指标。
Cancer Manag Res. 2020 Sep 17;12:8555-8568. doi: 10.2147/CMAR.S273065. eCollection 2020.
6
Fibrinogen/albumin ratio index is an independent predictor of recurrence-free survival in patients with intrahepatic cholangiocarcinoma following surgical resection.纤维蛋白原/白蛋白比值指数是肝内胆管癌患者手术后无复发生存的独立预测因子。
World J Surg Oncol. 2021 Jul 20;19(1):218. doi: 10.1186/s12957-021-02330-2.
7
The Prognostic Value of the Fibrinogen-Albumin-Ratio Index (FARI) in Patients with Advanced Vulvar Cancer.纤维蛋白原-白蛋白比值指数（FARI）在晚期外阴癌患者中的预后价值
J Pers Med. 2022 Nov 10;12(11):1882. doi: 10.3390/jpm12111882.
8
Fibrinogen/Albumin Ratio Index Is an Independent Prognosis Predictor of Recurrence-Free Survival in Patients After Surgical Resection of Gastrointestinal Stromal Tumors.纤维蛋白原/白蛋白比率指数是胃肠道间质瘤手术切除术后患者无复发生存的独立预后预测指标。
Front Oncol. 2020 Aug 18;10:1459. doi: 10.3389/fonc.2020.01459. eCollection 2020.
9
Fibrinogen-Albumin Ratio Index Exhibits Predictive Value of Neoadjuvant Chemotherapy in Osteosarcoma.纤维蛋白原-白蛋白比值指数显示出对骨肉瘤新辅助化疗的预测价值。
Cancer Manag Res. 2022 May 5;14:1671-1682. doi: 10.2147/CMAR.S358310. eCollection 2022.
10
The Predictive Value of the Fibrinogen-Albumin-Ratio Index on Surgical Outcomes in Patients with Advanced High-Grade Serous Ovarian Cancer.纤维蛋白原-白蛋白比值指数对晚期高级别浆液性卵巢癌患者手术结局的预测价值
Cancers (Basel). 2024 Sep 27;16(19):3295. doi: 10.3390/cancers16193295.

引用本文的文献

1
A New Risk Score Based on Lipid Indicators for Patients with Advanced Hepatocellular Carcinoma.一种基于脂质指标的晚期肝细胞癌患者新风险评分
J Hepatocell Carcinoma. 2025 Jan 21;12:107-121. doi: 10.2147/JHC.S505028. eCollection 2025.
2
Non-tumor-related prognostic factors for immunotherapy-chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC).免疫治疗联合化疗或免疫单药治疗作为晚期非小细胞肺癌（NSCLC）一线治疗的非肿瘤相关预后因素。
Clin Exp Med. 2024 Mar 15;24(1):52. doi: 10.1007/s10238-024-01298-z.
3
Pretreatment fibrinogen levels are associated with survival outcome in patients with cancer using immunotherapy as a second‑line treatment.

本文引用的文献

1
Preoperative albumin-to-fibrinogen ratio predicts severe postoperative complications in elderly gastric cancer subjects after radical laparoscopic gastrectomy.术前白蛋白-纤维蛋白原比值可预测老年胃癌患者根治性腹腔镜手术后严重术后并发症。
BMC Cancer. 2019 Sep 18;19(1):931. doi: 10.1186/s12885-019-6143-x.
2
Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel.系统免疫炎症指数、血清白蛋白和纤维蛋白原对一线多西他赛治疗的去势抵抗性前列腺癌患者预后的影响。
Int Urol Nephrol. 2019 Dec;51(12):2189-2199. doi: 10.1007/s11255-019-02265-4. Epub 2019 Aug 27.
3
使用免疫疗法作为二线治疗的癌症患者，治疗前的纤维蛋白原水平与生存结果相关。
Oncol Lett. 2023 May 5;25(6):269. doi: 10.3892/ol.2023.13855. eCollection 2023 Jun.
4
The Fibrinogen/Albumin Ratio Index as an Independent Prognostic Biomarker for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgery.纤维蛋白原/白蛋白比值指数作为肝内胆管癌合并肝细胞癌患者术后独立的预后生物标志物
Cancer Manag Res. 2022 May 23;14:1795-1806. doi: 10.2147/CMAR.S361462. eCollection 2022.
Fibrinogen-Albumin Ratio Index (FARI): A More Promising Inflammation-Based Prognostic Marker for Patients Undergoing Hepatectomy for Colorectal Liver Metastases.
纤维蛋白原-白蛋白比值指数（FARI）：一种用于预测结直肠癌肝转移患者行肝切除术预后的更有前途的炎症标志物。
Ann Surg Oncol. 2019 Oct;26(11):3682-3692. doi: 10.1245/s10434-019-07586-3. Epub 2019 Jul 1.
4
Prognostic significance of neutrophil-to lymphocyte ratio and platelet-to lymphocyte ratio in older patients with metastatic colorectal cancer.中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值对老年转移性结直肠癌患者预后的意义。
J Geriatr Oncol. 2019 Sep;10(5):742-748. doi: 10.1016/j.jgo.2018.10.002. Epub 2018 Oct 13.
5
NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.NCCN 指南解读：小细胞肺癌，2018 年版 2.0
J Natl Compr Canc Netw. 2018 Oct;16(10):1171-1182. doi: 10.6004/jnccn.2018.0079.
6
The predictive and prognostic role of a novel ADS score in esophageal squamous cell carcinoma patients undergoing esophagectomy.一种新型ADS评分在接受食管切除术的食管鳞状细胞癌患者中的预测和预后作用。
Cancer Cell Int. 2018 Oct 3;18:153. doi: 10.1186/s12935-018-0648-2. eCollection 2018.
7
Identifying the role of neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio as prognostic markers in patients undergoing resection of pancreatic ductal adenocarcinoma.确定中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值在接受胰腺导管腺癌切除术患者中作为预后标志物的作用。
Ann Hepatobiliary Pancreat Surg. 2018 Aug;22(3):197-207. doi: 10.14701/ahbps.2018.22.3.197. Epub 2018 Aug 31.
8
NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018.NCCN 指南解读：结直肠癌筛查，版本 1.2018.
J Natl Compr Canc Netw. 2018 Aug;16(8):939-949. doi: 10.6004/jnccn.2018.0067.
9
Prognostic significance of the fibrinogen-to-albumin ratio in gallbladder cancer patients.纤维蛋白原与白蛋白比值对胆囊癌患者的预后意义。
World J Gastroenterol. 2018 Aug 7;24(29):3281-3292. doi: 10.3748/wjg.v24.i29.3281.
10
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.基于血液的肿瘤突变负担可预测接受阿替利珠单抗治疗的非小细胞肺癌患者的临床获益。
Nat Med. 2018 Sep;24(9):1441-1448. doi: 10.1038/s41591-018-0134-3. Epub 2018 Aug 6.